Effective antibody-drug conjugates (ADC) combine high drug-linker stability in circulation
and efficient intratumoral release of drug. Conjugation of monomethyl auristatin E (MMAE) to …

Purpose: An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE)
conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties …

Antibody-drug conjugates (ADCs) made with auristatin antimitotic agents have shown
significant preclinical and clinical oncology activity. SGN-75 is composed of the anti-CD70 …

Antibody–drug conjugates (ADCs) have demonstrated clinical benefits that have led to the
recent FDA approval of KADCYLA and ADCETRIS. Most ADCs that are currently in clinical …

We have previously shown that antibody− drug conjugates (ADCs) consisting of cAC10 (anti-
CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro …

The chimeric monoclonal antibody cAC10, directed against CD30, induces growth arrest of
CD30+ cell lines in vitro and has pronounced antitumor activity in severe combined …

Abstract Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via
chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this …

The systemic stability of the antibody–drug linker is crucial for delivery of an intact antibody–
drug conjugate (ADC) to target-expressing tumors. Linkers stable in circulation but readily …

Purpose: We are interested in identifying mechanisms of resistance to the current generation
of antibody–drug conjugates (ADC) and developing ADCs that can overcome this …

Anti-CD30 diabodies were engineered with two cysteine mutations for site-specific drug
conjugation in each chain of these homodimeric antibody fragments. Diabodies were …